![Dr. Miguel Fernandez de Ullivarri](/sites/default/files/styles/portrait/public/medien/speakers/fw22labmiguelfernandezdeullivarri806x1075.jpg?h=42584ab7&itok=ldtVcCYE)
Dr. Miguel Fernandez de Ullivarri
Dr. Miguel Fernandez de Ullivarri was born in Argentina. After graduating with a BSc in Biotechnology in 2010, he obtained his PhD in Biochemistry at Universidad Nacional de Tucuman in 2015, studying the antimicrobial killer toxins produced by native wine yeasts from Northwestern Argentina. Dr. Fernandez de Ullivari carried out his first postdoctoral research at INSIBIO, Argentina, on the recombinant expression antigens from the parasite Leishmania braziliensis for the development of novel vaccines for Leishmaniasis. In 2018, he moved to Cork, Ireland as a Marie Curie Fellow to work at APC Microbiome in University College Cork with Prof. Paul Cotter, where he started his current project on novel antifungal peptides for the treatment of vaginal candidiasis. Dr. Fernandez de Ullivarri is still working on this and other applied science projects on antimicrobials, such as the use of Nisin A and phage endolysins for inhibition of specific pathogens along with the companies ImmuCell (USA) and Janssen (USA).